Urothelial Cancer

Eleven cases were positive (7.3%) with weak to intermediate score while all the cases of breast carcinoma (150/150; 100%) expressed TRPS-1 with intermediate to high scores. It was concluded that TRPS1 is 100% sensitive and 92.66% specific for breast carcinoma and can be included in the panel for search of unknown primary at metastatic site.

Adjuvant ADC+ICI showed comparable short-term OS and directionally favorable DFS/PFS trends versus GC, with a distinct toxicity profile. These findings are hypothesis-generating and require prospective validation.

P3, N=367, Active, not recruiting, CG Oncology, Inc. | Trial primary completion date: Jun 2026 --> Nov 2026

Although HER2-targeted therapies, such as trastuzumab deruxtecan, have shown promising results in HER2-positive bladder cancer, optimal immunohistochemistry (IHC) scoring criteria for urothelial carcinoma remain unclear...Upper GI and breast scoring criteria yield divergent scores in a significant subset of urothelial carcinomas, potentially affecting eligibility for targeted therapy. Associations with histologic subtype and metastatic site support disease-specific diagnostic and therapeutic strategies.

P=N/A, N=589, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> Nov 2025 | Trial primary completion date: Jan 2027 --> Nov 2025

P1, N=12, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting | Trial completion date: Feb 2026 --> Feb 2027

She was successfully treated with high-dose glucocorticoids, mycophenolate mofetil, and intravenous immunoglobulin with resolution of presenting symptoms...Additionally, we identified a differentiated CD27- CD28- effector memory (EM) CD4+ subset that was associated with clinical disease activity and contracted with glucocorticoid use administration. This illustrates a unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide insight into the underlying pathophysiology of irAEs, and to guide and gauge response to immunomodulatory therapy, thus facilitating a precision medicine approach within the diagnostic and treatment framework for irAEs.

Personalized, tumor-informed ctDNA testing can indicate response to EV±P and is prognostic of survival benefit in patients with la/mUC receiving EV±P.

P=N/A, N=150, Recruiting, University of California, Davis | Trial completion date: Jan 2031 --> Jan 2035 | Trial primary completion date: Dec 2025 --> Dec 2029

By integrating eight miRNA ratios with blood biochemistry parameters, the physiology-informed miRNA framework demonstrated promising diagnostic performance in the HD population. These findings link circulating miRNA signatures to UC-associated pathophysiology and support their potential for clinical detection, pending further external validation.

P=N/A, N=2500, Recruiting, Convergent Genomics, Inc.

These data provide a comprehensive overview on the prevalence on homozygous and heterozygous 9p21 deletions in cancer and demonstrate that different cancer types markedly differ in their ratio of homozygous/heterozygous 9p21 deletions. The strong concordance between homozygous 9p21 deletions and absent MTAP immunostaining highlights the effectiveness of immunohistochemistry in detecting MTAP deficiency.